RE: FUD works both ways8 Mar 2023 15:17
What if we get a msssive license deal for AVA3996? Is it a massive pump them? Excuse my ignorance but how is less than 500m for a share with cash right into 2024, showing proof of concept for a platform worth potentially 10s of billions, a pump? It isn’t. The drop has come from Avacta seeming to kick the can down the road. But the new trial design means phase P1b is actually of phase 2 design. So it’s nothing like as far down the road as the FUDers are leading people to believe. Was it a pump at 180? No. Why? Because the end goal moving down the line was unknown before SD. Absolutely nobody saw that coming. Nobody at all. It’s been cheered by all who understand it, inc Avacta, but since cash is King on AIM we’ve had a drop. If immediately on the release of SD data we’d have been into the next DE and the timelines hadn’t changed, we’d be well north of where we are now. So again, it’s never a pump when using the available information to assess where the SP should be. SNG, ADV, HE1. All pump and dumps but once the terrible RNS have been released. ITS is another one. The difference is they are all binary plays. This isn’t. We aren’t peering into a well hoping that liquid is oil or helium etc. We arent relying on one product to get us through. We’ve got AVA6000 in trial and awaiting DE, more data, etc. AVA3996 ready to go clinical with data to be released soon, possibly in April. DW, LG and Point moving our tech along without our imput. Launch is profitable and a stand alone business. And a TMAC update massively overdue. So this isn’t a pump and dump at all. It’s anyone’s guess when each piece of news/data will land. That label is being used by amateur analysts to Chuck mud on Avacta and class it as no better than the above. It’s a developing business that is doing extremely well progressing it’s IP through clinic. 6 biopsies showing genuinely therapeutic levels of Dox, often in huge concentrations compared to plasma, in 100% of samples taken is not a pump and dump. At all.
Sign In
Follow the stocks
